Silence Therapeutics plc

Silence Therapeutics plcverified

SLN

Price:

$18.31

Market Cap:

$645.03M

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatmen...[Read more]

Industry

Biotechnology

IPO Date

2020-09-08

Stock Exchange

NASDAQ

Ticker

SLN

The Enterprise Value as of September 2024 (TTM) for Silence Therapeutics plc (SLN) is 535.74M

According to Silence Therapeutics plc’s latest financial reports and current stock price. The company's current Enterprise Value is 535.74M. This represents a change of 9.93% compared to the average of 487.35M of the last 4 quarters.

Silence Therapeutics plc (SLN) Historical Enterprise Value (quarterly & annually)

How has SLN Enterprise Value performed in the past?

The mean historical Enterprise Value of Silence Therapeutics plc over the last ten years is 340.41M. The current 535.74M Enterprise Value has changed 15.64% with respect to the historical average. Over the past ten years (40 quarters), SLN's Enterprise Value was at its highest in in the March 2024 quarter at 647.18M. The Enterprise Value was at its lowest in in the September 2020 quarter at 0.

Quarterly (TTM)
Annual

Average

340.41M

Median

344.14M

Minimum

193.47M

Maximum

452.85M

Silence Therapeutics plc (SLN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Silence Therapeutics plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 42.52%

Maximum Annual Enterprise Value = 452.85M

Minimum Annual Increase = -21.88%

Minimum Annual Enterprise Value = 193.47M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023452.85M28.83%
2022351.51M-21.88%
2021449.95M9.27%
2020411.79M16.00%
2019355.00M5.41%
2018336.77M14.64%
2017293.77M-10.58%
2016328.52M42.52%
2015230.50M19.14%
2014193.47M23.57%

Silence Therapeutics plc (SLN) Average Enterprise Value

How has SLN Enterprise Value performed in the past?

The current Enterprise Value of Silence Therapeutics plc (SLN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

418.10M

5-year avg

404.22M

10-year avg

340.41M

Silence Therapeutics plc (SLN) Enterprise Value vs. Peers

How is SLN’s Enterprise Value compared to its peers?

Silence Therapeutics plc’s Enterprise Value is greater than Cidara Therapeutics, Inc. (-77580827.00), less than Applied Therapeutics, Inc. (796.79M), greater than CytomX Therapeutics, Inc. (59.90M), less than Shattuck Labs, Inc. (0), greater than C4 Therapeutics, Inc. (119.72M), greater than Eliem Therapeutics, Inc. (450.85M), greater than Prelude Therapeutics Incorporated (332.22M), greater than Monte Rosa Therapeutics, Inc. (130.69M), greater than Opthea Limited (319.09M), less than Centessa Pharmaceuticals plc (622.16M), less than Nuvalent, Inc. (1.75B), less than Tarsus Pharmaceuticals, Inc. (7.13B), less than Genfit S.A. (1.21B), greater than Avidity Biosciences, Inc. (179.29M), less than IGM Biosciences, Inc. (4.78B), less than Cerevel Therapeutics Holdings, Inc. (994.17M), less than Cullinan Oncology, Inc. (8.24B), less than Mineralys Therapeutics, Inc. (927.81M), greater than null (533.84M),

Build a custom stock screener for Silence Therapeutics plc (SLN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Silence Therapeutics plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Silence Therapeutics plc (SLN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Silence Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Silence Therapeutics plc's Enterprise Value?

What is the highest Enterprise Value for Silence Therapeutics plc (SLN)?

What is the 3-year average Enterprise Value for Silence Therapeutics plc (SLN)?

What is the 5-year average Enterprise Value for Silence Therapeutics plc (SLN)?

How does the current Enterprise Value for Silence Therapeutics plc (SLN) compare to its historical average?